

+

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	
			Filing Date	
			First Named Inventor	
			Group Art Unit	
			Examiner Name	
			Attorney Docket Number	
Sheet	2	of	4	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Akhlynina, T.V., Rosenkranz, A.A., Jans, D.A., Sobolev, A.S. Insulin-mediated intracellular targeting enhances the photodynamic activity of chlorin e6. Cancer Res 55:1014-1019	
		Bachor, R., Shea, C.R., Gillies, R., Hasan, T. Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres. Proc Natl	
		Cavanaugh, P.G. and Nicolson, G. L. Lung derived growth factor that stimulates the growth of lung-metastasizing tumor cells: Identification as transferrin. Journal of Cellular	
		Cavanaugh, P.G., and Nicolson, G.L. The selection of a metastatic rat mammary adenocarcinoma cell line from a low metastatic parental population by an in vitro process based on cellular ability to proliferate in response to transferrin. Journal of Cellular Physiology. 174: 48-57 1998.	
		Cavanaugh, P.G., Jia, L., and Nicolson, G.L. Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line. Breast Cancer Research and Treatment 56:203-217, 1999.	
		Conrad, M.E., and Umbreit, J.N. Iron absorption and transport-an update. Am J Hematol 64:287-298, 2000.	
		Del Governatore, M., Hamblin, M.R., Shea, C.R., Rizvi, I., Molpus, K.G., Tanabe, K.K., and Hasan, T. Experimental photodynamic therapy of hepatic metastases of colorectal cancer with a 17.1Å chlorin(e6) immunoconjugate. Cancer Res 60:4200-4205, 2000.	
		Donald, P.J., Cardiff, R.D., He, D.E., Kendall, K. Monoclonal antibody-porphyrin conjugate for head and neck cancer: the possible magic bullet. Otolaryngol Head Neck Surg 105:781-787 1991.	
		Elliot, R. L., Stjernholm, R., and Elliot, M. C. Preliminary evaluation of platinum transferrin (MTPC-63) as a potential nontoxic treatment for breast cancer. Cancer Detect. Prev. 12: 469-480, 1988	
		Gatter, K.C., Brown, G., Trowbridge, I.S., Woolston, R.E., Mason, D.Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 36: 539-545. 1983.	
		Gijssens, A., De Witte, P. Targeting of chlorine E6 by EGF increasing its photodynamic activity in selective ways. Verh K Acad Geneesk Belg 62:329-352, 2000.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	
			Filing Date	
			First Named Inventor	
			Group Art Unit	
			Examiner Name	
			Attorney Docket Number	
Sheet	3	of	4	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Greenberg, G.R., and Hilfinger, J.M. Regulation of synthesis of ribonucleotide reductase and relationship to DNA replication in various systems. Prog. in Nucleic Acid Res. 53: 345-395, 1996.	
		Hamblin, M.R., and Newman, E.L. Photosensitizer targeting in photodynamic therapy. I. conjugates of haematoporphyrin with albumin and transferrin. J. Photochem Photobiol B. 26: 45-56, 1994.	
		Hudson, P.J. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 11:548-557, 1999.	
		Hsi, R.A., Rosenthal, D.I., Glatstein, E. Photodynamic therapy in the treatment of cancer: current state of the art. Drugs 57:725-734 1999.	
		Katsumi, T., Aizawa, K., Okunaka, T., Kuroiwa, Y., Li, Y., Saito, K., Konaka, C., and Kato, H. Photodynamic therapy using a diode laser with mono-L-aspartyl chorin e6 for implanted fibrosarcoma in mice. Jpn J Cancer Res. 85:1165-1170, 1994.	
		Kemp, J.D., Smith, K.M., Mayer, J.M., Gomez, F., Thorson, J.A., and Naumann, P.W. Effects of anti-transferrin receptor antibodies on the growth of neoplastic cells. Pathobiology 60:27-32, 1992.	
		Kemp, J. D., Cardillo, T., Stewart, B. C., Kehrberg, S. E., Weiner, G., Hedlund, B., and Naumann, P. W. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 55: 3817-3824, 1995.	
		Kovar, J., Naumann, P.W., Stewart, B.C., and Kemp, J.D. Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. Pathobiology 63: 65-70, 1995.	
		Niitsu, Y., Kohgo, Y., Nishisato, T., Kondo, H., Kato, J., Urushizaki, Y., and Urushizaki, I. Transferrin receptors in human cancerous tissues. Tohoku J Exp Med 153:239-243, 1987.	
		Ponka, P., Beaumont, C., and Richardson, D.R. Function and regulation of transferrin and ferritin. Seminars in Hematology 35: 35-54, 1998.	
		Ponka, P., and Lok, C.N. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 31: 1111-1137, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	
				First Named Inventor	
				<input type="checkbox"/> <small>Individual Inventor</small>	
				<input type="checkbox"/> <small>Joint Inventor</small>	
Sheet	4	<input type="checkbox"/>	4	<input type="checkbox"/> <small>Individual Inventor</small>	
				<input type="checkbox"/> <small>Joint Inventor</small>	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Rossi, M. C. and Zetter, B. R. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc. Natl. Acad. Sci. USA, 89: 6197-6201, 1992.
		Scott, A.M., Welt, S. Antibody-based immunological therapies. Curr Opin Immunol 9:717-722, 1997.
		Seymour, G. J., Walsh, M. D., Lavin, M. F., Strutton, G., and Gardiner, R. A. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol. Res. 15: 341-344,
		Singh, M. Transferrin as a targetin ligand for liposomes and anticancer drugs. Curr Pharm Des 5:443-451, 1999.
		Stackpole CW, Kalbag SS, Groszek L: Acquisition of in vitro growth autonomy during B16 melanoma malignant progression is associated with autocrine stimulation by transferrin and fibronectin. In Vitro Cell Dev Biol 31: 244-251, 1995
		Testa, U., Pelosi, E., and Peschle, C. The transferrin receptor. Crit. Rev. Oncog., 4:241-276, 1993.
		Van Muijen, G. N., Ruiter, D. J., Hoefakker, S. and Johnson J. P. Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker for metastasis. J. Invest. Dermatol. 95: 65-69, 1990.
		Van Muijen, G. N. P., Jansen, K. F. J., Cornelissen, I. M. H. A., Smeets, D. F. C. M., Beck, J. L. M., and Ruiter, D. J. Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int. J. Cancer 48: 85-91, 1991.
		Wrba, F., Ritzinger, E., Reiner, A., and Holzner, J. H. Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. An immunohistochemical study. Virchows Arch. 41: 69-73, 1986.
		Yoda, J., Yamnaka, N., Saito, T., Samukawa, T., Tamura, S., and Kawaguchi, T. Characterization of cell lines from metastatic maxillary cancer. Journal of the Oto-Rhino-Laryngological Society of Japan 97: 419-429, 1994.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.